Stock report · Delisted · Nasdaq
Marinus Pharmaceuticals Inc (MRNS)
0.55USD Delisted Final close · Feb 10, 2025
MRNS no longer trades. Marinus Pharmaceuticals was delisted from the Nasdaq in February 2025.
All prices on this page are historical. The last trade was on February 10, 2025, at $0.55.
MRNS stock price history
Final trading statistics
- Final close
- $0.55
- Final trading day
- Feb 10, 2025
- Market cap at delisting
- $30.37M
- Shares outstanding
- 55.22M
- Final 52-week range
- $0.22 – $10.50
- Avg. volume (final 3 mo.)
- 1,794,805
- All-time high
- $77.52 · Aug 2015
- All-time low
- $0.23 · Dec 2024
- Return since IPO
- -98.3%
- Beta
- 1.26
- Book value / share
- $0.31
- Price / book
- 1.79
About Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals developed and sold treatments for rare genetic epilepsies and other seizure disorders. Its product ZTALMY (ganaxolone) was an oral suspension for seizures linked to CDKL5 deficiency disorder in adults and children, usable in hospital and at-home settings. Ganaxolone acts on synaptic and extrasynaptic GABAA receptors.
The company was also studying ganaxolone in other genetic epilepsies, such as PCDH19-related epilepsy and tuberous sclerosis complex. It had license deals with Purdue Neuroscience and CyDex Pharmaceuticals and collaborations with Orion Corporation and Tenacia Biotechnology (Shanghai).
Marinus was incorporated in 2003 and based in Radnor, Pennsylvania. Its stock was delisted from the Nasdaq in February 2025, with the last trade on February 10, 2025 at $0.55.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Radnor, PA
- Employees
- 165
- IPO date
- July 31, 2014
- Delisted
- February 10, 2025
- SEC CIK
- 1267813
Marinus Pharmaceuticals financials before the delisting
The last 5 fiscal years Marinus Pharmaceuticals reported as a public company, fiscal year ending December.
MRNS revenue and net income
MRNS earnings per share
MRNS annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $30.99M | −$141.4M | −$2.63 |
| FY2022 | $25.48M | −$19.8M | −$3.28 |
| FY2021 | $15.35M | −$101.7M | −$2.69 |
| FY2020 | $1.72M | −$66.6M | −$2.58 |
| FY2019 | $0.00 | −$53.8M | −$3.96 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Marinus Pharmaceuticals stock FAQ
What happened to Marinus Pharmaceuticals stock?
Marinus Pharmaceuticals was delisted from the Nasdaq in February 2025. The final close was $0.55 on February 10, 2025.
Can I still buy MRNS stock?
No. MRNS is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on February 10, 2025.
What was the last price of MRNS?
MRNS last closed at $0.55 on February 10, 2025, which valued the company at about $30.37M.
How did Marinus Pharmaceuticals do in its last full fiscal year?
In fiscal 2023, its last full year as a public company, Marinus Pharmaceuticals reported revenue of $30.99M and net income of −$141.4M.
When did Marinus Pharmaceuticals go public?
Marinus Pharmaceuticals shares started trading on July 31, 2014.
MRNS no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.